Fat Science

What happens when GLP-1 medications stop working the way you hoped they would? In this mailbag episode, Dr. Emily Cooper answers listener questions about fasting, insulin levels, PCOS, lipedema, plateaus on Zepbound, and the complicated reality behind metabolic dysfunction. From the dangers of under-fueling to why individualized treatment matters so much, this conversation unpacks the science behind weight resistance with clarity and compassion.Key TakeawaysWhy fasting and restrictive eating may worsen metabolic adaptationThe real role insulin plays in metabolic healthHow PCOS and lipedema complicate weight loss treatmentWhy some people plateau on GLP-1 medications over timeThe importance of fueling, muscle preservation, and individualized careLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told your metabolism is broken and there's nothing you can do about it?This mailbag episode tackles tough questions about medication effectiveness, unexpected side effects, and the complex realities of treating metabolic dysfunction. Dr. Cooper addresses why some people regain weight while still on GLP-1s, explores the connection between hair loss and weight loss medications, and explains why leptin levels can remain stubbornly low even with proper nutrition.KEY TAKEAWAYSWeight regain while on GLP-1 medications is more common than most people realizeHair loss from weight loss medications is usually related to nutrient deficiencies, not the medication itselfLeptin dysfunction involves both hormone levels and signaling pathways throughout the bodyHypoglycemia after meals often indicates complex metabolic issues that require specialized testingStarting elderly patients on GLP-1s requires careful monitoring of nutrition, blood pressure, and side effectsMechanical eating differs from intuitive eating and remains important even when medications are workingAnnual weight loss rates of 10% or higher indicate medications are still effectiveNOTABLE QUOTE"It is not uncommon to see the weight go up while on these meds, contrary to what people think. They're great, but we always wanna point out some people don't even respond to these." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told you have PCOS but nothing seems to help?In May 2024, after 14 years of global collaboration involving 56 organizations and 22,000 stakeholders, the medical community officially changed PCOS to PMOS - and the reason why reveals everything that's been wrong with how this condition has been understood and treated for decades. Dr. Cooper breaks down why this isn't just a name change, but a complete reframe that puts metabolic dysfunction at the center where it belongs.KEY TAKEAWAYSPCOS is now officially called PMOS - Polyendocrine Metabolic Ovarian Syndrome - shifting focus from ovarian problems to metabolic dysfunction70 million women globally are affected during reproductive years, with 70% remaining undiagnosedThe condition can occur at any weight and is driven by insulin resistance and other metabolic signals, not ovarian problemsTreatment should focus on metabolic health rather than weight loss or ovarian interventionsThe name change parallels similar shifts in medicine like MASLD replacing non-alcoholic fatty liver diseaseNOTABLE QUOTE"Most patients with this label that they've had in the past, the PCOS label, feel a sense of hopelessness, and even join support groups and things like that, and thinking that this will be a condition they have forever. And what I try to do is explain, no, this is just a physical manifestation of the metabolic disruption that we treat all the time" — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are your legs painful to touch and resistant to weight loss despite your best efforts?Dr. Ellen Derrick, a vascular surgeon and lipedema specialist, reveals the truth about this misunderstood condition affecting 20% of women worldwide. Lipedema isn't obesity - it's a fat cell disorder where tissue responds abnormally to inflammation, creating painful, swollen areas that don't respond to traditional weight loss methods. She explains the connection between lipedema and venous insufficiency, why patients are often dismissed by doctors, and the emerging treatments offering hope.KEY TAKEAWAYSLipedema affects 20% of the female population but is routinely misdiagnosed as obesityThe condition involves abnormal fat cell response to inflammation, creating painful tissue that resists weight loss86% of lipedema patients also have venous insufficiency, creating a perfect storm of symptomsAnkle cuffs, knee pouches, and saddlebags are classic physical signs that patients often notice from pubertyGLP-1 medications like tirzepatide may help reduce inflammation and tissue tendernessLipedema reduction surgery exists but lacks insurance billing codes, making access challengingA formal medical recognition campaign is underway to establish diagnostic codes by 2026-2027NOTABLE QUOTE"The medical community really has done an outstanding job, in a way, gaslighting these patients. These patients have been aware that something is different about their body and their legs since puberty." — Dr. Ellen DerrickGUEST BIODr. Ellen Derrick is a Seattle-based board-certified vascular and general surgeon with over 20 years of clinical experience and a Master of Public Health from the University of Washington. She founded Boxbar Vascular, specializing in lipedema and related metabolic conditions, and serves on the board of the Lipedema Society working toward formal medical recognition of the condition.Links & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you ever wondered if you should get liposuction when you need skin removal surgery after major weight loss?In this mailbag episode, Dr. Cooper, Mark, and Andrea tackle questions from listeners around the world, from Germany to Alabama to Chicago. They discuss why restricting calories while on GLP-1 medications can actually work against you, address the reality of finding metabolic-informed doctors internationally, and explain the science behind fat cell removal during skin surgeries. Plus, they share details about the newly approved oral GLP-1 medication orforglipron (Foundayo) and why vegetables, fats and starches matter even when you're protein-focused.KEY TAKEAWAYSRestricting calories on GLP-1 medications can lower your metabolic rate and weaken your body's natural GLP-1 productionLiposuction during skin removal surgery may disrupt leptin signaling, though males may be less affected than females due to naturally lower leptin levelsFinding metabolic-informed doctors globally remains challenging, but obesity medicine certification and Canadian and European obesity organizations may offer better resourcesThe oral GLP-1 medication orforglipron will likely be less expensive but also less effective than dual-agonist medications like tirzepatideMechanical eating without calorie counting often produces better long-term results than restrictive approachesVegetables provide essential micronutrients and support healthy microbiome function that protein alone cannot replaceMajor weight loss surgery like tummy tucks is serious surgery that requires careful consideration and qualified surgeonsNOTE: This episode was recorded before Foundayo (orforglipron) was released on the market. The price is the same as the Wegovy pill. Listen to our episode - “New Obesity Drugs” for more information https://podcasts.apple.com/us/podcast/fat-science/id1715377331?i=1000762362056NOTABLE QUOTE"If only they didn't fall into that diet cycle, some of them, their weight would be a hundred pounds less. Yes, it might be still elevated, but a large chunk of that weight was caused by the diet cycle itself." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The obesity medication landscape just changed — again. One brand-new pill is already in pharmacies, and five more are in various stages of approval. But the real story isn't the drugs themselves: it's what they're revealing about how your metabolism actually works, and why willpower was never the problem.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down six metabolic medications — two newly FDA-approved and four in the pipeline — covering everything from a flexible new oral GLP-1 pill to drugs that target the brain's central metabolic pathway directly. Dr. Cooper explains the science behind each one, who might benefit, and what the pipeline tells us about the future of metabolic care. This is the most comprehensive drug update the show has done, and it arrives at a moment when the field is moving faster than ever.Key TakeawaysFoundayo (orforglipron), approved April 1st, is the first small molecule oral GLP-1 — no empty stomach requirement, no cold chain, and potentially lower production costs long-term.The amylin hormone may uniquely address both "I'm nourished" and "I weigh enough" signals in the brain — making the amylin pathway a powerful and underutilized target.Retatrutide (Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors) is showing unprecedented effectiveness plus significant non-scale benefits, including fatty liver reduction — but is still years from approval.The brain's melanocortin 4 receptor is the CEO of metabolism — regulating energy expenditure, appetite, and insulin — and new drugs targeting it represent the deepest intervention yet.Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost.Notable Quote"Everybody focuses on appetite, and you just need to eat less. But now with these medications and how they actually affect our biology, it becomes very clear that there's so much more to this." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Are you getting a GLP-1 prescription from someone who's never examined you?Dr. Vin Gupta, pulmonologist and former Chief Medical Officer at Amazon, joins Dr. Cooper to expose the dangerous gap between legitimate obesity medicine and the unregulated direct-to-consumer market. This conversation reveals why proper medical evaluation matters and how profit-driven platforms are exploiting desperate patients.KEY TAKEAWAYSGLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribingDirect-to-consumer microdosing platforms lack FDA approval and proper medical oversightThe erosion of trust in healthcare has created opportunities for unregulated treatmentsComprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plansTechnology should enhance medical care, not replace proper physician evaluationNOTABLE QUOTE"I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." — Dr. Emily CooperGUEST BIODr. Vin Gupta is a pulmonologist, public health expert, and medical analyst for NBC News. He served as Chief Medical Officer at Amazon and has dedicated his career to translating complex science into actionable health insights at both individual and population levels.GLOSSARYGLP-1 medications: Glucagon-like peptide-1 receptor agonists, medications that help regulate blood sugar and appetite, including brand names like Ozempic, Wegovy, and ZepboundMicrodosing: Taking smaller amounts of medication than officially prescribed or approvedDirect-to-consumer (D2C): Healthcare services that bypass traditional medical settings, often delivered through apps or online platformsHRV: Heart rate variability, a measurement of the variation in time between heartbeatsPre-diabetes: Blood sugar levels that are higher than normal but not high enough to be diagnosed as type 2 diabetesLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Ever wonder why fasting worked at first — then stopped? Or why you lost 80 pounds only to gain back 100?In this mailbag episode, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the most misunderstood topics in metabolic health. From the harsh reality of fasting culture to the surprising metabolic challenges faced by normal-weight individuals, this conversation validates what you've been experiencing and explains the science behind it. You'll also hear why GLP-1 medications aren't just weight loss drugs, why your body might be fighting you even when you're doing everything right, and what happens when your job — like shift work or firefighting — disrupts your metabolism for years.KEY TAKEAWAYSYou can have metabolic dysfunction at a normal weight with what appear to be normal labs, for example, when insulin is over suppressed from chronic under-fueling or overexercisingFasting triggers the same biological adaptation as any restrictive diet and typically results in weight regain that's 22 percent higher than starting weightFood noise is biological, not psychological, and stems from an imbalance of hormones and neurotransmitters signaling nutritional insecurityGLP-1 medications may improve immune function because metabolic health and immunity are deeply connectedShift work and chronic sleep disruption can cause real metabolic damage by weakening leptin signals, increasing insulin resistance, and amplifying hunger hormonesNOTABLE QUOTE"You can't trick your body. You have to have that foundational fueling in there." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Think squashing your post-meal glucose spike is the healthy thing to do? What if that flat line on your CGM is actually telling your brain you didn't eat — and slowing your metabolism as a result?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor open the mailbag to tackle listener questions from around the world — Australia, New Zealand, and across the U.S. They dig into hormone replacement therapy and metabolism, why your GLP-1 medication might be causing hair loss, what a normal blood sugar response actually looks like, and how lipedema differs from obesity. Dr. Cooper also revisits metabolic syndrome and why it's not outdated — just underutilized.Key TakeawaysHormone replacement therapy isn't a reliable tool for improving metabolism — it's better suited for symptom relief and bone health in specific situations.Progesterone, which must accompany estrogen if you still have your uterus, can actually disrupt metabolism in some women — acting almost like a steroid.A flat glucose line after eating isn't the goal — your brain needs to see glucose go up to register that you've been nourished and keep your metabolism running.Hair loss on GLP-1 medications is more likely tied to nutrient deficiencies (especially iron and protein) than the drugs themselves.Lipedema is a disease of the fat tissue itself — separate from obesity — and tirzepatide may help reduce the inflammatory symptoms even though it won't eliminate the fat deposits.Notable Quote"If your glucose is flat line, your brain's not very convinced that you ate much — and then you're not getting the metabolic benefit." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

The Science Behind the New Wegovy Pill (with Novo Nordisk’s Dr. Jason Brett)What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.Key TakeawaysOral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.The “30-minute rule” isn’t random—it’s part of how the pill has a chance to work as intended.Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”Pricing and access shape who can actually benefit, even when the science is strong.Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.Notable Quote"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark WrightLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Wegovy Pill: Who's It For?The new Wegovy pill is generating massive buzz — but is it actually better than the injection? Before you ask your doctor to switch, there are some surprising requirements that could make or break whether this option works for you.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the new oral semaglutide approved for obesity treatment. They explain how the Wegovy pill differs from Rybelsus, who's a good candidate to switch (and who isn't), the strict dosing protocol most people don't know about, and what's coming next in the GLP-1 pill landscape — including a less fussy competitor from Eli Lilly.Key TakeawaysThe Wegovy pill uses an upgraded "version two" formulation with enhanced absorption — it's not the same as RybelsusSemaglutide targets deep metabolic dysfunction, not just appetite — reducing inflammation, visceral fat, and cardiovascular riskThe pill must be taken first thing in the morning on an empty stomach with minimal water, then nothing else for 30 minutes — breaking this protocol negates effectivenessThe pill is slightly less effective than the highest-dose Wegovy injection, so switching isn't ideal for patients still making progress at maximum doseNovo Nordisk's cash pay program starts at $149/month for lower doses and $299/month for the highest doseEli Lilly's upcoming orforglipron pill uses small molecule technology that won't require the strict dosing ritualNotable Quote"When people say it works because it just makes you eat less, that's really missing the point of the sophistication of these meds." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions from California, the UK, France, Washington, Wyoming, and beyond. The team breaks down why Dr. Cooper does not recommend calorie tracking (and when limited tracking can make sense), how to build confidence in eating without data, and why “mechanical eating” sometimes needs medical customization—especially for people with slow gut transit or gastroparesis-like symptoms. They also dig into bile acid malabsorption after gallbladder removal, when metformin side effects deserve a second look, what we currently know about COVID-19’s potential impact on metabolic health, and why metformin and GLP-1 medications can be complementary—particularly in PCOS.Key Takeaways• Long-term calorie tracking can override physiologic cues and reinforce diet mentality.• Short-term, targeted tracking may be useful when guided by a clinician (e.g., nutrient deficiencies ).• Obesity and abnormal appetite are both manifestations of metabolic dysfunction—not simple cause and effect.• Mechanical eating is a framework, not a rigid rule—timing and food choices may need medical tailoring.• Post-gallbladder diarrhea may reflect bile acid malabsorption and can be treatable.• Metformin and GLP-1s often complement each other because they target different metabolic states (fasting vs fed).Dr. Cooper’s Actionable Tips• Stop daily calorie counting—focus on consistent patterns and metabolic nourishment.• Use mechanical eating basics: eat every few hours, include all food groups, and reduce chemical additives when possible.• If you’re transitioning away from tracking, consider a dietitian skilled in diet-mentality recovery.• If frequent eating worsens sleep or bloating, work with a medical dietitian to adjust intervals and food types (especially with slow GI transit).• If chronic diarrhea appears (especially after gallbladder removal), ask your clinician about bile acid malabsorption and treatment options.• Use labs to guide therapy: fasting insulin can signal metformin benefit; post-meal patterns can point toward GLP-1 needs.Notable Quote“Once you start using tracking to stay in a calorie range or a carbohydrate range, you’re putting your brain in front of your physiologic intuition—your body is sending you important cues all the time.”—Dr. Emily CooperLinks & ResourcesThe Metabolic Links to PCOS, Release Date 2/24/25The COVID Connection to Diabetes & Metabolic Health, Release Date 12/16/24Podcast Home: https://fatsciencepodcast.com/Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Question: questions@fatsciencepodcast.com*Fat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down two GLP-1 studies that challenge a major media myth: GLP-1 medications don’t drive weight loss just because people eat less. Instead, drugs like tirzepatide and semaglutide create direct metabolic shifts—including increased fat oxidation and improved fuel partitioning—regardless of appetite.The team also explores mechanical eating, the psychological impact of “diet food,” and Andrea’s 13-year metabolic recovery journey.Key Questions AnsweredIf both groups are dieting, why does the tirzepatide group lose more weight?What is metabolic adaptation, and why does dieting slow metabolism so sharply?How do GLP-1s directly increase fat oxidation?What is mechanical eating, and why do GLP-1 users need it?Why does ad-lib eating produce different metabolic responses than calorie restriction?Can mindset alone change hunger hormones? (Yes—the milkshake study.)Why do diet foods and diet sodas fail to improve metabolic health?Why is response to GLP-1s so different from person to person?Key TakeawaysGLP-1s are metabolic drugs—not appetite suppressants.Their power comes from hormonal effects on fat burning, not reduced food intake.Calorie restriction still slows metabolism.Even on GLP-1s, dieting triggers significant metabolic slowdown.Ad-lib eating outperforms dieting in the research.Semaglutide users who ate freely did not show the extra metabolic slowdown seen in dieters.Mechanical eating is the most durable long-term approach.Regular meals and snacks protect lean mass and prevent famine signaling.Mindset shapes hormones.Believing a food is “diet” vs. “indulgent” alters ghrelin and satisfaction.Track body composition—not just the scale.DEXA scans show whether you’re losing fat, muscle, or bone.Dr. Cooper’s Actionable TipsDon’t diet on GLP-1s. Focus on fueling, not restriction.Use mechanical eating: predictable meals and snacks, no long gaps.Prioritize satisfaction: diet foods often backfire hormonally.Follow your real-world data: long-term changes matter more than short-term scale shifts.Ask about body composition testing if possible.Notable Quote:“What that study proved is that doing the calorie restriction is causing the metabolic slowing… and that’s why it’s so confusing to me that we keep advising people to restrict calories when they’re trying to improve their metabolic function.” —Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Question: questions@fatsciencepodcast.comDr. Cooper Email: dr.c@fatsciencepodcast.comFat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational only, and is not intended to be medical advice.